MindMed Will Use the Proceeds of the Offering for Investment in its Digital Medicine Division, for Further Investments in its Project Lucy and Project Layla, for its LSD Micro-Dosing ADHD Trials and for General Working Capital Purposes
MindMed (OTCQB:MMEDF) announced that further to its previously announced offering on December 14 and December 15, 2020, it has filed a preliminary short form prospectus with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement among the company, the underwriters Canaccord Genuity and Eight Capital have agreed to purchase 18,200,000 units of the company, on a bought deal basis, at a price per unit of CDN $4.40 for gross proceeds of CDN $80.08 million.